Compare PCRX & TROX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | TROX |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.5B |
| IPO Year | 2010 | 2012 |
| Metric | PCRX | TROX |
|---|---|---|
| Price | $23.78 | $9.27 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 8 |
| Target Price | ★ $30.25 | $6.50 |
| AVG Volume (30 Days) | 518.7K | ★ 3.2M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 2.10% |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | $541,533,000.00 | ★ $2,898,000,000.00 |
| Revenue This Year | $6.78 | $6.25 |
| Revenue Next Year | $8.54 | $5.39 |
| P/E Ratio | $150.19 | ★ N/A |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $2.86 |
| 52 Week High | $27.99 | $9.94 |
| Indicator | PCRX | TROX |
|---|---|---|
| Relative Strength Index (RSI) | 57.59 | 60.62 |
| Support Level | $23.74 | $3.10 |
| Resistance Level | $23.94 | $9.94 |
| Average True Range (ATR) | 0.73 | 0.52 |
| MACD | 0.11 | -0.02 |
| Stochastic Oscillator | 75.36 | 54.03 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Tronox Holdings PLC is a vertically integrated manufacturer of TiO2 pigment. It operates titanium-bearing mineral sand mines and beneficiation and smelting operations in Australia & South Africa to produce feedstock materials that can be processed into TiO2 for pigment, high-purity titanium chemicals, including titanium tetrachloride, and ultrafine TiO2 used in certain specialty applications. TiO2 and titanium feedstock, are used to produce paints and coatings, as well as plastics, paper, and printing ink. It has three pigment production facilities in the United States, the Netherlands, and Western Australia and three mining operations in Western Australia and South Africa. Europe, the Middle East, and Africa regions contribute the majority of revenue.